Samsung Biologics Agrees to Buy PolyPeptide in $1.8 Billion Deal
Samsung Biologics Co. has agreed to acquire Switzerland’s PolyPeptide Group AG in an all-cash deal that values the contract drugmaker’s equity at about 1.46 billion Swiss francs ($1.8 billion), expanding...
By Denny Thomas · Bloomberg
Samsung Biologics Co. has agreed to acquire Switzerland’s PolyPeptide Group AG in an all-cash deal that values the contract drugmaker’s equity at about 1.46 billion Swiss francs ($1.8 billion), expanding its manufacturing capabilities.